{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:14:39Z","timestamp":1789478079403,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Acne is a chronic inflammatory disease mainly observed in adolescence,\nbut it can also be seen during the neonatal, infantile, pre-pubertal, and adult periods.\nIsotretinoin (13-cis-retinoic acid) is a first-generation retinoid and is the most effective treatment\nfor acne vulgaris.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The present study has been systematically designed to figure out the toxic, genotoxic,\nand carcinogenic activities of isotretinoin.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>In this study, a systematic approach was followed by focusing on the possible links\nbetween these topics. The search of the databases was carried out author in accordance with\nthe guidelines of the Centre for Reviews and Dissemination (2009) developed by York University\nNational Institute of Health Research. The search was concentrated on the Web of Science,\nPubMed, Science Direct, Scopus, EBSCO Host, and Google Scholar databases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Isotretinoin was found as a toxic agent in all studies. All researchers proposed that\napoptosis is the only pathway of adverse effects of isotretinoin. However, genotoxicity, teratogenicity,\nand carcinogenicity information of isotretinoin is very limited and controversial.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>More detailed studies need to clarify the genotoxic and carcinogenic potential of\nisotretinoin. Patients should be informed correctly, the risks of treatment should be explained,\nand awareness should be raised.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874467215666220520143124","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T05:16:26Z","timestamp":1653628586000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Toxicity, Genotoxicity, and Carcinogenicity of Isotretinoin"],"prefix":"10.1016","volume":"16","author":[{"given":"Serkan","family":"Yilmaz","sequence":"first","affiliation":[{"name":"Faculty of Nursing, Institute for Forensic Sciences, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.colsurfb.2012.12.043","volume":"105","author":"Raza K.","year":"2013","unstructured":"Raza K.; Singh B.; Singal P.; Wadhwa S.; Katare O.P.; Sys-tematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids Surf B Biointerfaces 2013,105,67-74","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=2","first-page":"177-179","volume":"39","year":"2000","unstructured":"Akne vulgaris\u2019de isotretinoin tedavisi ile al\u0131nan sonu&#xE7;lar. Ege T\u0131p Dergisi Ertam, \u0130.; Alper, S.; Ceylan, C2000,39,177-179","journal-title":"Ege T\u0131p Dergisi"},{"key":"ref=3","author":"Saylan T.","year":"1991","unstructured":"Saylan T.;  Skin and venereal diseases for physicians Hand-book in 1st Level Health Services 1991","journal-title":"Skin and venereal diseases for physicians Hand-book in 1st Level Health Services"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000246016","volume":"195","author":"Meigel W.N.","year":"1997","unstructured":"Meigel W.N.; How safe is oral isotretinoin? Dermatology 1997,195(Suppl. 1),22-28","journal-title":"Dermatology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000246018","volume":"195","author":"Ortonne J.P.","year":"1997","unstructured":"Ortonne J.P.; Oral isotretinoin treatment policy. Do we all agree? Dermatology 1997,195(Suppl. 1),34-37","journal-title":"Dermatology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0733-8635(05)70016-4","volume":"16","author":"Saurat J.H.","year":"1998","unstructured":"Saurat J.H.; Systemic retinoids. What\u2019s new? Dermatol Clin 1998,16(2),331-340","journal-title":"Dermatol Clin"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00003495-199448010-00006","volume":"48","author":"Sykes N.L.","year":"1994","unstructured":"Sykes N.L.; Webster G.F.; Acne. A review of optimum treatment. Drugs 1994,48(1),59-70","journal-title":"Drugs"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0190-9622(08)80252-6","volume":"27","author":"Layton A.M.","year":"1992","unstructured":"Layton A.M.; Cunliffe W.J.; Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 1992,27(6 Pt 2)(Suppl.),S2-S7","journal-title":"J Am Acad Dermatol"},{"key":"ref=9","first-page":"1","volume":"14","author":"Jr W.W.","year":"1984","unstructured":"Jr W.W.; Tunnessen, Acne: An approach to therapy for the pediatrician. Curr Probl Pediatr 1984,14,1-36","journal-title":"Curr Probl Pediatr"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jaad.2004.02.012","volume":"50","author":"Goldsmith L.A.","year":"2004","unstructured":"Goldsmith L.A.; Bolognia J.L.; Callen J.P.; Chen S.C.; Feld-man S.R.; Lim H.W.; Lucky A.W.; Reed B.R.; Siegfried E.C.; Thiboutot D.M.; Wheeland R.G.; American academy of dermatology. American academy of dermatology consensus conference on the safe and optimal use of isotretinoin: Sum-mary and recommendations. J Am Acad Dermatol 2004,50(6),900-906","journal-title":"J Am Acad Dermatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.clindermatol.2009.03.005","volume":"28","author":"Rigopoulos D.","year":"2010","unstructured":"Rigopoulos D.; Larios G.; Katsambas A.D.; The role of isotretinoin in acne therapy: Why not as first-line therapy? facts and controversies. Clin Dermatol 2010,28(1),24-30","journal-title":"Clin Dermatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/1523-1747.ep12519851","volume":"74","author":"Strauss J.S.","year":"1980","unstructured":"Strauss J.S.; Stranieri A.M.; Farrell L.N.; Downing D.T.; The effect of marked inhibition of sebum production with 13cis-retinoic acid on skin surface lipid composition. J Invest Dermatol 1980,74(2),66-67","journal-title":"J Invest Dermatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/sj.jid.5700289","volume":"126","author":"Nelson A.M.","year":"2006","unstructured":"Nelson A.M.; Gilliland K.L.; Cong Z.; Thiboutot D.M.; 13-cis Retinoic acid induces apoptosis and cell cycle arrest in hu-man SEB-1 sebocytes. J Invest Dermatol 2006,126(10),2178-2189","journal-title":"J Invest Dermatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/archderm.142.8.1016","volume":"142","author":"Zane L.T.","year":"2006","unstructured":"Zane L.T.; Leyden W.A.; Marqueling A.L.; Manos M.M.; A population-based analysis of laboratory abnormalities during isotretinoin therapy for Acne vulgaris. Arch Dermatol 2006,142(8),1016-1022","journal-title":"Arch Dermatol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/ajg.2010.124","volume":"105","author":"Crockett S.D.","year":"2010","unstructured":"Crockett S.D.; Porter C.Q.; Martin C.F.; Sandler R.S.; Kap-pelman M.D.; Isotretinoin use and the risk of inflammatory bowel disease: A case-control study. Am J Gastroenterol 2010,105(9),1986-1993","journal-title":"Am J Gastroenterol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamadermatol.2019.1416","volume":"155","author":"Singer S.","year":"2019","unstructured":"Singer S.; Tkachenko E.; Sharma P.; Barbieri J.S.; Mostagh-imi A.; Psychiatric adverse events in patients taking isotret-inoin as reported in a food and drug administration database from 1997 to 2017. JAMA Dermatol 2019,155(10),1162-1166","journal-title":"JAMA Dermatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0190-9622(88)70078-X","volume":"18","author":"Bigby M.","year":"1988","unstructured":"Bigby M.; Stern R.S.; Adverse reactions to isotretinoin. A report from the adverse drug reaction reporting system. J Am Acad Dermatol 1988,18(3),543-552","journal-title":"J Am Acad Dermatol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jaad.2016.12.028","volume":"76","author":"Huang Y.C.","year":"2017","unstructured":"Huang Y.C.; Cheng Y.C.; Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. J Am Acad Dermatol 2017,76(6),1068-1076.e9","journal-title":"J Am Acad Dermatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4161\/derm.1.3.9364","volume":"1","author":"Layton A.","year":"2009","unstructured":"Layton A.; The use of isotretinoin in acne. Dermatoendocrinol 2009,1(3),162-169","journal-title":"Dermatoendocrinol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/cbf.2830","volume":"30","year":"2012","unstructured":"Erturan, \u0130 Naziro&#x11F;lu, M.; Akkaya, V.B. Isotretinoin treatment induces oxidative toxicity in blood of patients with Acne vul-garis: A clinical pilot study. Cell Biochem Funct 2012,30(7),552-557","journal-title":"Cell Biochem Funct"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.fct.2005.02.016","volume":"43","author":"Ferguson S.A.","year":"2005","unstructured":"Ferguson S.A.; Cisneros F.J.; Gough B.J.; Ali S.F.; Four weeks of oral isotretinoin treatment causes few signs of gen-eral toxicity in male and female Sprague-Dawley rats. Food Chem Toxicol 2005,43(8),1289-1296","journal-title":"Food Chem Toxicol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.rbmo.2013.04.010","volume":"27","author":"Abali R.","year":"2013","unstructured":"Abali R.; Yuksel M.A.; Aktas C.; Celik C.; Guzel S.; Erfan G.; Sahin O.; Decreased ovarian reserve in female Sprague-Dawley rats induced by isotretinoin (retinoic acid) exposure. Reprod Biomed Online 2013,27(2),184-191","journal-title":"Reprod Biomed Online"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.aott.2018.06.006","volume":"52","author":"Beytem&#xFC;r O.","year":"2018","unstructured":"Beytem&#xFC;r O.; Y&#xFC;ksel S.; Tetikkurt &#xDC;.S.; Gen&#xE7; E.; Olcay E.; G&#xFC;le&#xE7; A.; Isotretinoin induced achilles tendinopathy: Histo-pathological and biomechanical evaluation on rats. Acta Orthop Traumatol Turc 2018,52(5),387-391","journal-title":"Acta Orthop Traumatol Turc"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3923\/ijp.2019.706.715","volume":"15","author":"Ibrahim Al-Othman S.","year":"2019","unstructured":"Ibrahim Al-Othman S.; Nasser Bin-Jumah M.; Abdullah Alk-osome, R. Deleterious effects of perinatal exposure to isotret-inoin drug on the offspring of pregnant mice. Int J Pharmacol 2019,15(6),706-715","journal-title":"Int J Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3892\/etm.2015.2203","volume":"9","author":"Kim S.K.","year":"2015","unstructured":"Kim S.K.; Shin S.J.; Yoo Y.; Kim N.H.; Kim D.S.; Zhang D.; Park J.A.; Yi H.; Kim J.S.; Shin H.C.; Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice. Exp Ther Med 2015,9(3),853-859","journal-title":"Exp Ther Med"},{"key":"ref=26","first-page":"158","volume":"56","year":"2018","unstructured":"Kuma&#x15F; M.; E&#x15F;refo&#x11F;lu, M.; G&#xFC;ler, E.M. Protective effects of silymarin against isotretinoin induced liver and kidney injury in mice. Indian J Exp Biol 2018,56,158-163","journal-title":"Indian J Exp Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3109\/15376516.2014.937514","volume":"24","author":"Saied N.M.","year":"2014","unstructured":"Saied N.M.; Hamza A.A.; Selenium ameliorates isotretinoin-induced liver injury and dyslipidemia via antioxidant effect in rats. Toxicol Mech Methods 2014,24(6),433-437","journal-title":"Toxicol Mech Methods"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10863-013-9517-9","volume":"45","author":"Silva F.S.G.","year":"2013","unstructured":"Silva F.S.G.; Ribeiro M.P.C.; Santos M.S.; Rocha-Pereira P.; Santos-Silva A.; Cust&#xF3;dio J.B.A.; The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced per-meability transition and bioenergetic dysfunction of liver mito-chondria: comparison with tamoxifen. J Bioenerg Biomembr 2013,45(4),383-396","journal-title":"J Bioenerg Biomembr"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0161-4754(99)70088-6","volume":"22","author":"Brandt J.R.","year":"1999","unstructured":"Brandt J.R.; Mick T.J.; Extraspinal enthesopathy caused by isotretinoin therapy. J Manipulative Physiol Ther 1999,22(6),417-420","journal-title":"J Manipulative Physiol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1186\/2193-1801-3-698","volume":"3","author":"Graf S.W.","year":"2014","unstructured":"Graf S.W.; Whittle S.L.; Isotretinoin-induced skeletal hyperos-tosis. Springerplus 2014,3(1),698-701","journal-title":"Springerplus"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1067\/mjd.2001.113721","volume":"45","author":"DiGiovanna J.J.","year":"2001","unstructured":"DiGiovanna J.J.; Isotretinoin effects on bone. J Am Acad Dermatol 2001,45(5),S176-S182","journal-title":"J Am Acad Dermatol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/01480545.2014.905590","volume":"38","author":"Ozkol H.U.","year":"2015","unstructured":"Ozkol H.U.; Ozkol H.; Karadag A.S.; Bilgili S.G.; Tuluce Y.; Calka O.; Oral isotretinoin therapy of acne patients decreases serum paraoxonase-1 activity through increasing oxidative stress. Drug Chem Toxicol 2015,38(1),63-66","journal-title":"Drug Chem Toxicol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0377-1237(10)80038-3","volume":"66","author":"Kumar A.","year":"2010","unstructured":"Kumar A.; Kumar V.K.; Toxicity of low-dose intermittent isotretinoin in recalcitrant acne. Med J Armed Forces India 2010,66(3),208-212","journal-title":"Med J Armed Forces India"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/SMJ.0b013e318172f64c","volume":"101","author":"Finsterer J.","year":"2008","unstructured":"Finsterer J.; Enhanced ocular isotretinoin toxicity in mitochon-drial disorder. South Med J 2008,101(6),664-665","journal-title":"South Med J"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.canlet.2005.06.047","volume":"229","author":"Arce F.","year":"2005","unstructured":"Arce F.; G&#xE4;tjens-Boniche O.; Vargas E.; Valverde B.; D&#xED;az C.; Apoptotic events induced by naturally occurring retinoids ATRA and 13-cis retinoic acid on human hepatoma cell lines Hep3B and HepG2. Cancer Lett 2005,229(2),271-281","journal-title":"Cancer Lett"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.1067\/mjd.2001.113720","volume":"45","author":"Nau H.","year":"2001","unstructured":"Nau H.; Teratogenicity of isotretinoin revisited: Species varia-tion and the role of all-trans-retinoic acid. J Am Acad Dermatol 2001,45(5),S183-S187","journal-title":"J Am Acad Dermatol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/15513819609169308","volume":"16","author":"Coberly S.","year":"1996","unstructured":"Coberly S.; Lammer E.; Alashari M.; Retinoic acid embryopa-thy: Case report and review of literature. Pediatr Pathol Lab Med 1996,16(5),823-836","journal-title":"Pediatr Pathol Lab Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000248878","volume":"175","author":"Shalita A.R.","year":"1987","unstructured":"Shalita A.R.; Mucocutaneous and systemic toxicity of retin-oids: Monitoring and management. Dermatologica 1987,175(Suppl. 1),151-157","journal-title":"Dermatologica"},{"key":"ref=39","first-page":"533","volume":"33","author":"Heilgemeir G.P.","year":"1982","unstructured":"Heilgemeir G.P.; Braun-Falco O.; Plewig G.; Sund M.; Effect of 13-cis-retinoic acid on hair growth. Hautarzt 1982,33(10),533-536","journal-title":"Hautarzt"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5114\/pdia.2013.39432","volume":"30","year":"2013","unstructured":"Kmie\u0107 M.L.; Pajor, A.; Broniarczyk-Dy\u0142a, G. Evaluation of biophysical skin parameters and assessment of hair growth in patients with acne treated with isotretinoin. Postepy Dermatol Alergol 2013,30(6),343-349","journal-title":"Postepy Dermatol Alergol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/000155501317140070","volume":"81","author":"Landau M.","year":"2001","unstructured":"Landau M.; Mesterman R.; Ophir J.; Mevorah B.; Alcalay J.; Harel A.; Nevo Y.; Clinical significance of markedly elevat-ed serum creatine kinase levels in patients with acne on isotret-inoin. Acta Derm Venereol 2001,81(5),350-352","journal-title":"Acta Derm Venereol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1365-4632.2008.03491.x","volume":"47","author":"Kaymak Y.","year":"2008","unstructured":"Kaymak Y.; Creatine phosphokinase values during isotretinoin treatment for acne. Int J Dermatol 2008,47(4),398-401","journal-title":"Int J Dermatol"},{"key":"ref=43","first-page":"94","volume":"125","author":"Heudes A.M.","year":"1998","unstructured":"Heudes A.M.; Laroche L.; Muscular damage during isotret-inoin treatment. Ann Dermatol Venereol 1998,125(2),94-97","journal-title":"Ann Dermatol Venereol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/febs.13771","volume":"283","author":"Blander J.M.","year":"2016","unstructured":"Blander J.M.; Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease. FEBS J 2016,283(14),2720-2730","journal-title":"FEBS J"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2340\/00015555-2535","volume":"97","author":"Melnik B.C.","year":"2017","unstructured":"Melnik B.C.; Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol 2017,97(2),173-181","journal-title":"Acta Derm Venereol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.tiv.2013.01.002","volume":"27","author":"Silva F.S.G.","year":"2013","unstructured":"Silva F.S.G.; Oliveira H.; Moreiras A.; Fernandes J.C.; Bronze-da-Rocha E.; Figueiredo A.; Cust&#xF3;dio J.B.A.; Rocha-Pereira P.; Santos-Silva A.; The in vitro and in vivo genotoxici-ty of isotretinoin assessed by cytokinesis blocked micronucle-us assay and comet assay. Toxicol In Vitro 2013,27(2),900-907","journal-title":"Toxicol In Vitro"},{"key":"ref=47","first-page":"1675","volume":"26","author":"Derici Eker E.","year":"2019","unstructured":"Derici Eker E.; Kocoglu S.; Sahin N.O.; Investigation of geno-toxicity caused by oral isotretinoin use in acne treatment. Ann Med Res 2019,26,1675-1679","journal-title":"Ann Med Res"},{"key":"ref=48","first-page":"185","volume":"19","author":"Bordbar M.","year":"2020","unstructured":"Bordbar M.; Zendeh-Boodi Z.; Saadat M.; The in vivo geno-toxicity of isotretinoin assessed by comet assay. EXCLI J 2020,19,185-186","journal-title":"EXCLI J"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"100787","DOI":"10.1016\/j.ajoc.2020.100787","volume":"19","author":"Mishra K.K.","year":"2020","unstructured":"Mishra K.K.; Scholey J.E.; Daftari I.K.; Afshar A.; Tsai T.; Park S.; Quivey J.M.; Char D.H.; Oral isotretinoin and topical retinoid use in a series of young patients with ocular melano-ma. Am J Ophthalmol Case Rep 2020,19,100787","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1158\/1055-9965.EPI-10-0652","volume":"19","author":"Kaae J.","year":"2010","unstructured":"Kaae J.; Boyd H.A.; Hansen A.V.; Wulf H.C.; Wohlfahrt J.; Melbye M.; Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev 2010,19(11),2942-2949","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2003.08.008","volume":"50","author":"Fine J-D.","year":"2004","unstructured":"Fine J-D.; Johnson L.B.; Weiner M.; Stein A.; Suchindran C.; Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: Results of a phase 1 trial of systemic isotretinoin. J Am Acad Dermatol 2004,50(4),563-571","journal-title":"J Am Acad Dermatol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnci\/93.8.605","volume":"93","author":"Lippman S.M.","year":"2001","unstructured":"Lippman S.M.; Lee J.J.; Karp D.D.; Vokes E.E.; Benner S.E.; Goodman G.E.; Khuri F.R.; Marks R.; Winn R.J.; Fry W.; Graziano S.L.; Gandara D.R.; Okawara G.; Woodhouse C.L.; Williams B.; Perez C.; Kim H.W.; Lotan R.; Roth J.A.; Hong W.K.; Randomized phase III intergroup trial of isotret-inoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001,93(8),605-618","journal-title":"J Natl Cancer Inst"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1056\/NEJM198612113152401","volume":"315","author":"Hong W.K.","year":"1986","unstructured":"Hong W.K.; Endicott J.; Itri L.M.; Doos W.; Batsakis J.G.; Bell R.; Fofonoff S.; Byers R.; Atkinson E.N.; Vaughan C.; Toth B.B.; Kramer A.; Dimery I.W.; Skipper P.; Strong S.; 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986,315(24),1501-1505","journal-title":"N Engl J Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJM199009203231205","volume":"323","author":"Hong W.K.","year":"1990","unstructured":"Hong W.K.; Lippman S.M.; Itri L.M.; Karp D.D.; Lee J.S.; Byers R.M.; Schantz S.P.; Kramer A.M.; Lotan R.; Peters L.J.; Dimery I.W.; Brown B.W.; Goepfert H.; Prevention of second primary tumors with isotretinoin in squamous-cell car-cinoma of the head and neck. N Engl J Med 1990,323(12),795-801","journal-title":"N Engl J Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJM199301073280103","volume":"328","author":"Lippman S.M.","year":"1993","unstructured":"Lippman S.M.; Batsakis J.G.; Toth B.B.; Weber R.S.; Lee J.J.; Martin J.W.; Hays G.L.; Goepfert H.; Hong W.K.; Com-parison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993,328(1),15-20","journal-title":"N Engl J Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/jnci\/86.2.140","volume":"86","author":"Benner S.E.","year":"1994","unstructured":"Benner S.E.; Pajak T.F.; Lippman S.M.; Earley C.; Hong W.K.; Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Long-term follow-up. J Natl Cancer Inst 1994,86(2),140-141","journal-title":"J Natl Cancer Inst"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/bjc.1996.568","volume":"74","author":"Rustin G.J.S.","year":"1996","unstructured":"Rustin G.J.S.; Quinnell T.G.; Johnson J.; Clarke H.; Nel-strop A.E.; Bollag W.; Trial of isotretinoin and calcitriol moni-tored by CA 125 in patients with ovarian cancer. Br J Cancer 1996,74(9),1479-1481","journal-title":"Br J Cancer"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00259-001-0702-4","volume":"29","author":"Boerner A.R.","year":"2002","unstructured":"Boerner A.R.; Petrich T.; Weckesser E.; Fricke H.; Hof-mann M.; Otto D.; Weckesser M.; Langen K.J.; Knapp W.H.; Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002,29(2),231-236","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dth.12062","volume":"27","author":"Skroza N.","year":"2014","unstructured":"Skroza N.; Proietti I.; Tolino E.; Bernardini N.; La Viola G.; Nicolucci F.; Pampena R.; Mancini M.T.; Balduzzi V.; Po-tenza C.; Zuber S.; Isotretinoin for the treatment of squamous cell carcinoma arising on an epidermoid cyst. Dermatol Ther 2014,27(2),94-96","journal-title":"Dermatol Ther"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJM199412223312503","volume":"331","author":"Castleberry R.P.","year":"1994","unstructured":"Castleberry R.P.; Emanuel P.D.; Zuckerman K.S.; Cohn S.; Strauss L.; Byrd R.L.; Homans A.; Chaffee S.; Nitschke R.; Gualtieri R.J.; A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 1994,331(25),1680-1684","journal-title":"N Engl J Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/1078155213483348","volume":"20","author":"Chen S.E.","year":"2014","unstructured":"Chen S.E.; Choi S.S.; Rogers J.E.; Lei X.; De Groot J.F.; Isotretinoin maintenance therapy for glioblastoma: A retro-spective review. J Oncol Pharm Pract 2014,20(2),112-119","journal-title":"J Oncol Pharm Pract"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874467215666220520143124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205086\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874467215666220520143124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:58:10Z","timestamp":1746572290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205086\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467215666220520143124","relation":{},"ISSN":["1874-4672"],"issn-type":[{"value":"1874-4672","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}